{
    "organizations": [],
    "uuid": "9686da472024d1479040e52dd5cbb7165dfffb00",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-novimmune-fda-accepts-emapalumab-b/brief-novimmune-fda-accepts-emapalumab-biologics-license-application-with-priority-review-idUSFWN1SZ00R",
    "ord_in_thread": 0,
    "title": "BRIEF-Novimmune: FDA Accepts Emapalumab Biologics License Application With Priority Review",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 28 (Reuters) - Novimmune SA ( IPO-NOVI.S ):\n* FDA ACCEPTS EMAPALUMAB BIOLOGICS LICENSE APPLICATION WITH PRIORITY REVIEW Source text: bit.ly/2lagxU7 Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-05-28T13:08:00.000+03:00",
    "crawled": "2018-05-30T11:14:19.006+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "novimmune",
        "sa",
        "fda",
        "accepts",
        "emapalumab",
        "biologics",
        "license",
        "application",
        "priority",
        "review",
        "source",
        "text",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}